HCA Healthcare, Inc. (HCA)
NYSE: HCA · Real-Time Price · USD
473.19
-4.89 (-1.02%)
At close: Oct 30, 2026, 4:00 PM EDT
475.61
+2.42 (0.51%)
After-hours: Oct 30, 2026, 7:46 PM EDT
HCA Healthcare Stock Forecast
Stock Price Forecast
According to 26 analysts polled by S&P Global, HCA Healthcare stock has a consensus rating of "Buy" and an average price target of $469.91. The average 1-year stock price forecast is 0.69% lower than the current stock price, while the lowest is $380 (-19.69%) and the highest is $550 (+16.23%).
Price Target: $469.91 (-0.69%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for HCA Healthcare stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 13 | 13 | 13 | 13 | 14 | 14 |
| Buy | 2 | 2 | 1 | 1 | 1 | 1 |
| Hold | 9 | 9 | 10 | 10 | 10 | 9 |
| Sell | 0 | 0 | 0 | 0 | 0 | 1 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 25 | 25 | 25 | 25 | 26 | 26 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $496 → $521 | Buy | Maintains | $496 → $521 | +10.10% | Oct 30, 2026 |
| Barclays | Barclays | Hold Maintains $387 → $401 | Hold | Maintains | $387 → $401 | -15.26% | Oct 29, 2026 |
| TD Cowen | TD Cowen | Buy Maintains $460 → $486 | Buy | Maintains | $460 → $486 | +2.71% | Oct 28, 2026 |
Unknown Analyst Oppenheimer No rating | Oppenheimer | Buy Maintains $485 | Buy | Maintains | $485 | +2.50% | Oct 28, 2026 |
| BMO Capital | BMO Capital | Buy Reiterates $495 | Buy | Reiterates | $495 | +4.61% | Oct 28, 2026 |
Financial Forecast
Revenue This Year
79.10B
from 75.60B
Increased by 4.63%
Revenue Next Year
81.62B
from 79.10B
Increased by 3.19%
EPS This Year
30.11
from 28.21
Increased by 6.72%
EPS Next Year
31.36
from 30.11
Increased by 4.17%
EPS and Forward PE are based on non-GAAP adjusted numbers.